Posttransplantation MRD monitoring in patients with AML by next-generation sequencing using DTA and non-DTA mutations

समान संसाधन

• Measurable residual disease (MRD) monitoring by next-generation sequencing before allogeneic hematopoietic cell transplantation in AML
  द्वारा: Thol, Felicitas, और अन्य
  प्रकाशित: (2018)
• Acute myeloid leukemia derived from lympho-myeloid clonal hematopoiesis
  द्वारा: Thol, Felicitas, और अन्य
  प्रकाशित: (2017)
• FLA-IDA salvage chemotherapy combined with a seven-day course of venetoclax (FLAVIDA) in patients with relapsed/refractory acute leukaemia
  द्वारा: Shahswar, Rabia, और अन्य
  प्रकाशित: (2020)
• IDH1/2 mutations in acute myeloid leukemia patients and risk of coronary artery disease and cardiac dysfunction—a retrospective propensity score analysis
  द्वारा: Kattih, Badder, और अन्य
  प्रकाशित: (2020)
• getITD for FLT3-ITD-based MRD monitoring in AML
  द्वारा: Blätte, Tamara J., और अन्य
  प्रकाशित: (2019)